Bohan Ma
YOU?
Author Swipe
View article: Enhancing the Accuracy of Monopole and Dipole Source Identification with Vision Transformer
Enhancing the Accuracy of Monopole and Dipole Source Identification with Vision Transformer Open
The identification of mixed monopole and dipole sound sources under highly randomized acoustic environments is of interest in many industrial applications. The DAMAS–MS method is one of the few methods that has been explicitly developed to…
View article: Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia
Development of a selectively AURKB targeting peptide degradation drug with artificial intelligence-assisted design for the treatment of acute lymphoblastic leukemia Open
Our findings demonstrate that ATPD is the first AI-designed, selective AURKB degrader with potent anti-leukemic activity. This study highlights ATPD's potential as a novel, precise therapeutic strategy for the treatment of ALL, addressing …
View article: Enhancing the Accuracy of Monopole and Dipole Source Identification with Vision Transformer
Enhancing the Accuracy of Monopole and Dipole Source Identification with Vision Transformer Open
Identifications of mixed monopole and dipole sound sources under highly randomized acoustic environments are of interest in many industrial applications. The DAMAS–MS method is one of the few methods that has been explicitly developed to a…
View article: Supplementary Figure S2 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Figure S2 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Fig. S2. Design and characterization of the BRCA2-targeting peptide PROTAC drug. Related to Fig. 1.
View article: Supplementary Figure S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Figure S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Fig. S1. Design and characterization of the BRCA2-targeting peptide PROTAC drug. Related to Fig. 1.
View article: Supplementary Figure S3 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Figure S3 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Fig. S3. BPD effectively induces BRCA2 degradation. Related to Fig. 2.
View article: Supplementary Table S2 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Table S2 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Table S2. Somatic mutation analysis of WES of the PDX model.
View article: Supplementary Figure S5 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Figure S5 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Fig. S5. BPD sensitizes HR proficient prostate cancer cells to synthetic lethality by PARP inhibitors. Related to Fig. 5.
View article: Supplementary Figure S7 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Figure S7 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Fig. S7. BPD sensitizes HR proficient prostate cancer cells to synthetic lethality by PARP inhibitors. Related to Fig. 5.
View article: Supplementary Table S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Table S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Table S1. Clinical information of the PDX model.
View article: Supplementary Figure S4 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Figure S4 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Fig. S4. BPD induces BRCA2 degradation in a DDB1-dependent manner. Related to Fig. 3.
View article: Data from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Data from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Defects in homologous recombination repair (HR) make cells highly susceptible to PARP inhibitors. However, the limited efficacy of PARP inhibitors in targeting HR wild-type tumors restricts their broad utility in cancer treatment. Clinical…
View article: Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
Supplementary Figure S6 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition Open
Supplementary Fig. S6. Histological and immunofluorescent characterization of the prostate cancer PDX model. Related to Fig. 5.
View article: CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma
CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma Open
Polybromo 1 (PBRM1) inactivating mutations are associated with clinical benefit from immune checkpoint inhibitor treatments in clear cell renal cell carcinoma (ccRCC). However, whether targeting PBRM1 has the potential to enhance immunothe…
View article: DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity
DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity Open
53BP1 plays an important role in DNA double-strand break (DSB) repair and this activity is negatively regulated by its interaction with Tudor interacting repair regulator (TIRR). However, how the TIRR-53BP1 repair axis is regulated in resp…
View article: An Overview of Interactions between Goat Milk Casein and Other Food Components: Polysaccharides, Polyphenols, and Metal Ions
An Overview of Interactions between Goat Milk Casein and Other Food Components: Polysaccharides, Polyphenols, and Metal Ions Open
Casein is among the most abundant proteins in milk and has high nutritional value. Casein’s interactions with polysaccharides, polyphenols, and metal ions are important for regulating the functional properties and textural quality of dairy…
View article: CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity
CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity Open
DNA replication is a vulnerable cellular process, and its deregulation leads to genomic instability. Here, we demonstrate that chromobox protein homolog 3 (CBX3) binds replication protein A 32-kDa subunit (RPA2) and regulates RPA2 retentio…
View article: Development of a Double-Stapled Peptide Stabilizing Both α-Helix and β-Sheet Structures for Degrading Transcription Factor AR-V7
Development of a Double-Stapled Peptide Stabilizing Both α-Helix and β-Sheet Structures for Degrading Transcription Factor AR-V7 Open
Peptide drugs offer distinct advantages in therapeutics; however, their limited stability and membrane penetration abilities hinder their widespread application. One strategy to overcome these challenges is the hydrocarbon peptide stapling…
View article: EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma
EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma Open
The EZH2-regulated immune-risk score prognostic model was an independent prognostic factor, with good accuracy and predictability, and could provide experimental data to the clinical area.
View article: Photoactivatable metal organic framework for synergistic ferroptosis and photodynamic therapy using 450 nm laser
Photoactivatable metal organic framework for synergistic ferroptosis and photodynamic therapy using 450 nm laser Open
Photodynamic therapy (PDT) is an appealing treatment modality by producing reactive oxygen species (ROS) with photosensitizers (PSs) to induce cell apoptosis, but still suffering poor efficacy in treating hypoxic solid tumor. Herein, we ha…
View article: De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy
De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy Open
Androgen receptor splice variant‐7 (AR‐V7), one of the major driving factors, is the most attractive drug target in castration‐resistant prostate cancer (CRPC). Currently, no available drugs efficiently target AR‐V7 in clinical practice. T…
View article: Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive Leukemia
Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive Leukemia Open
The Bcr/Abl plays a central role in Philadelphia chromosome‐positive (Ph+) leukemia because of the constitutively activated Abl tyrosine kinase and its downstream pathways. Currently, the clinical treatment of imatinib‐resistant patients w…
View article: Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression Open
Rationale: Although stapled peptides offer a powerful solution to overcome the susceptibility of linear peptides to proteolytic degradation and improve their ability to cross membranes, an efficient and durable disease treatment strategy h…
View article: Transcriptional Profiles of Long Non-coding RNAs Involved in Fatty Acid Biosynthesis at Filling Stage of Soybean Pods
Transcriptional Profiles of Long Non-coding RNAs Involved in Fatty Acid Biosynthesis at Filling Stage of Soybean Pods Open
Background: Long non-coding RNAs (lncRNAs) are non-coding RNAs of more than 200 nucleotides. To date, the roles of lncRNAs in soybean fatty acid synthesis have not been fully studied. Here, the low-linolenic acid ‘mutant 72’ (MT72) and the…